Invest in

Drug-Patent Cliffs

8.4%
3.8%
1.2%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
8.4%
3.8%
1.2%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 7.4%
19.3% Taro Pharmaceutical Industries Ltd. TARO 16.6%
19.1% Dr. Reddy's Laboratories Ltd RDY 9.0%
14.9% Mylan N.V. MYL 6.2%
12.0% Akorn Inc. AKRX 8.9%
9.1% Abbott Laboratories ABT 20.0%
8.6% The Medicines Company MDCO 12.5%
5.8% Impax Laboratories Inc. IPXL 51.0%
3.5% Lannett Co Inc LCI 9.5%
2.9% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 41.1%
2.5% Mallinckrodt plc MNK 32.4%
1.2% Endo International PLC ENDP 21.9%
1.1% Cambrex Corporation CBM 8.4%

Quotes delayed 15 mins. Currently May 24, 2017 3:52:12 AM. Fields are marked with -- when data is unavailable.